Hit enter to search or ESC to close

Author: Alterity Therapeutics

Alterity Therapeutics commences US investor meetings following positive clinical data

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is today commencing an investor roadshow in the US.  The meetings follow the Company’s presentation of clinical data from its Phase 1 clinical trial program for its investigative drug PBT434 at the American Academy of Neurology Annual Meeting last week. The data indicate that ...